Does gestational diabetes increase the risk of maternal kidney disease? A Swedish national cohort study - PubMed (original) (raw)

Does gestational diabetes increase the risk of maternal kidney disease? A Swedish national cohort study

Peter M Barrett et al. PLoS One. 2022.

Abstract

Background: Gestational diabetes (GDM) is associated with increased risk of type 2 diabetes (T2DM) and cardiovascular disease. It is uncertain whether GDM is independently associated with the risk of chronic kidney disease. The aim was to examine the association between GDM and maternal CKD and end-stage kidney disease (ESKD) and to determine whether this depends on progression to overt T2DM.

Methods: A population-based cohort study was designed using Swedish national registry data. Previous GDM diagnosis was the main exposure, and this was stratified according to whether women developed T2DM after pregnancy. Using Cox regression models, we estimated the risk of CKD (stages 3-5), ESKD and different CKD subtypes (tubulointerstitial, glomerular, hypertensive, diabetic, other).

Findings: There were 1,121,633 women included, of whom 15,595 (1·4%) were diagnosed with GDM. Overall, GDM-diagnosed women were at increased risk of CKD (aHR 1·81, 95% CI 1·54-2·14) and ESKD (aHR 4·52, 95% CI 2·75-7·44). Associations were strongest for diabetic CKD (aHR 8·81, 95% CI 6·36-12·19) and hypertensive CKD (aHR 2·46, 95% CI 1·06-5·69). These associations were largely explained by post-pregnancy T2DM. Among women who had GDM + subsequent T2DM, strong associations were observed (CKD, aHR 21·70, 95% CI 17·17-27·42; ESKD, aHR 112·37, 95% CI 61·22-206·38). But among those with GDM only, associations were non-significant (CKD, aHR 1·11, 95% CI 0·89-1·38; ESKD, aHR 1·58, 95% CI 0·70-3·60 respectively).

Conclusion: Women who experience GDM and subsequent T2DM are at increased risk of developing CKD and ESKD. However, GDM-diagnosed women who never develop overt T2DM have similar risk of future CKD/ESKD to those with uncomplicated pregnancies.

PubMed Disclaimer

Conflict of interest statement

I have read the journal’s policy and the authors of this manuscript have the following competing interests: ME has participated in advisory board meetings (Astellas, Astra Zeneca, Vifor Pharma) and has received payment for lectures (Astellas, Vifor Pharma). This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Similar articles

Cited by

References

    1. IDF Diabetes Atlas Ninth Edition 2019. International Diabetes Federation.
    1. Noctor E, Dunne FP. Type 2 diabetes after gestational diabetes: The influence of changing diagnostic criteria. World J Diabetes. 2015;6(2):234–44. doi: 10.4239/wjd.v6.i2.234 - DOI - PMC - PubMed
    1. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, et al.. Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications. Circulation. 2019;139(8):1069–79. doi: 10.1161/CIRCULATIONAHA.118.036748 - DOI - PubMed
    1. Barrett PM, McCarthy FP, Kublickiene K, Cormican S, Judge C, Evans M, et al.. Adverse Pregnancy Outcomes and Long-term Maternal Kidney Disease: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(2):e1920964. doi: 10.1001/jamanetworkopen.2019.20964 - DOI - PubMed
    1. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med. 2010;268(5):456–67. doi: 10.1111/j.1365-2796.2010.02269.x - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources